Nothing Special   »   [go: up one dir, main page]

To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

From Wikipedia, the free encyclopedia

GSK1360707F
Identifiers
  • (1R,6S)-1-(3,4-Dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H17Cl2NO
Molar mass286.20 g·mol−1
3D model (JSmol)
  • COC[C@@]12C[C@@]1(CCNC2)c3ccc(c(c3)Cl)Cl
  • InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m0/s1
  • Key:ICXJGCSEMJXNQF-KBPBESRZSA-N
  (verify)

GSK1360707F is a potent and selective triple reuptake inhibitor.[1] It is chemically related to amitifadine and NS-2359 (GSK-372,475). Until recently,[when?] it was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.[citation needed]

Synthesis

Synthesis of GSK1360707F[2]
  1. BOC Protecting group.
  2. Enolization and trapping with triflate group (cf Comins' reagent).
  3. Suzuki reaction
  4. Reduction (only 1 mol eq. LAH because N-BOC can be reduced to N-Me)
  5. Trifluoroacetic acid (TFA) removal of protecting group.
  6. Simmons–Smith reaction cyclopropanation.
  7. Williamson ether synthesis (c.f. NS patents & paxil).

Transporter occupancy

GSK1360707F has recently (2013) been tested on baboons (Papio anubis) & humans for transporter occupancy using PET.[3]

See also

References

  1. ^ Micheli F, Cavanni P, Andreotti D, Arban R, Benedetti R, Bertani B, et al. (July 2010). "6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor". Journal of Medicinal Chemistry. 53 (13): 4989–5001. doi:10.1021/jm100481d. PMID 20527970.
  2. ^ WO 2008031772, Bertani, Barbara; Di Fabio, Romano & Micheli, Fabrizio et al., "Azabicyclic compounds as inhibitors of monoamines reuptake", published 2008-03-20, assigned to Glaxo Group Ltd. 
  3. ^ Comley RA, Salinas CA, Slifstein M, Petrone M, Marzano C, Bennacef I, et al. (August 2013). "Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography". The Journal of Pharmacology and Experimental Therapeutics. 346 (2): 311–7. doi:10.1124/jpet.112.202895. PMID 23685546. S2CID 2964324.
This page was last edited on 5 November 2022, at 14:02
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.